ENHERTU gains FDA approval for HER2 low or ultralow metastatic breast cancer treatment

Daiichi Sankyo and AstraZeneca’s ENHERTU (fam-trastuzumab deruxtecan-nxki) has secured approval from the U.S. Food and Drug Administration (FDA) for treating adults with unresectable or metastatic ... Read More